Metabolic safety of gender-affirming hormonal treatment in transgender females
Sexual Health · 29.08.2025 · 22 (4)
DOI: 10.1071/sh25113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sexual Health, online erschienen am 11.08.2025. Verfasst von Charalampos Milionis und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital 'Elena Venizelou', Athens, Attica, Greece. Hauptthemen laut MEDLINE: Estradiol, Testosterone, Transgender Persons, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Gender incongruence results from the mismatch between gender identity and thesex assigned at birth. The process of gender affirmation includes a series of procedures during which the transgender individual acquires phenotypic features of the desired sex. Hormonal therapy for transgender women aims to suppress endogenous androgens and replace them with estrogens. The present study sought to investigate the safety of feminizing therapy in transgender women in relation to somatometric and metabolic parameters.
Methods
The medical records of transgender women who received oral estradiol valerate and a gonadotropin-releasing hormone (GnRH) agonist for at least 18 months were reviewed. The study population had estradiol levels within the normal limits of the follicular phase of cisgender women of reproductive age and suppressed blood testosterone levels after 18 months of treatment. Changes in body mass index, glycemic and lipid profiles, hemoglobin and hematocrit, and liver function tests were examined. The paired t-test was used for statistical analysis.
Results
The mean blood estradiol and testosterone levels after approximately 18 months of treatment were 85.65 pg/mL and 24 ng/dL, respectively. There was a statistically significant increase in blood triglycerides as well as a statistically significant decrease in hemoglobin and hematocrit. However, none of the participants developed severe hypertriglyceridemia or anemia. No significant changes were found in blood cholesterol (total, high-density lipoprotein, and low-density lipoprotein cholesterol), glucose, and liver enzymes.
Conclusions
Treatment with oral estradiol valerate and an intramuscular GnRH agonist is used in daily clinical practice to promote feminizing physical changes in transgender women. However, the possibility of side effects is not well documented. The present study demonstrated that achieving estradiol and testosterone levels within therapeutic targets is important for the safety of gender-affirming therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- General Hospital 'Elena Venizelou', Athens, Attica, Greece.
Zitieren
APA
Milionis, C., Barouti, K., Papadopoulou, V., Pouliasi, F., Karlafti, E., Makrydima, S., Karampa, S., Venaki, E., & Koukkou, E. (2025). Metabolic safety of gender-affirming hormonal treatment in transgender females. Sexual Health, 22(4). https://doi.org/10.1071/sh25113
Vancouver
Milionis C, Barouti K, Papadopoulou V, Pouliasi F, Karlafti E, Makrydima S, et al. Metabolic safety of gender-affirming hormonal treatment in transgender females. Sexual Health. 2025;22(4). doi:10.1071/sh25113
BibTeX
@article{Milionis2025,
author = {Milionis, Charalampos and Barouti, Konstantina and Papadopoulou, Vassiliki and Pouliasi, Foteini and Karlafti, Efthymia and Makrydima, Sofia and Karampa, Stavroula and Venaki, Evaggelia and Koukkou, Eftychia},
title = {Metabolic safety of gender-affirming hormonal treatment in transgender females},
journal = {Sexual Health},
year = {2025},
volume = {22},
number = {4},
doi = {10.1071/sh25113}
}
EUVIMED